Livial® is a first choice comprehensive treatment for the relief of climacteric symptoms and prevention of osteoporosis in postmenopausal women as Livial® contains tibolone - a selective tissue estrogenic activity regulator (STEAR) - which regulates estrogenic activity in a tissue selective way. These tissue-selective properties of Livial enable it to provide effective relief of climacteric symptoms and vaginal atrophy, enhance mood and sexual well being and prevent osteoporosis. In the endometrium and breast tissue it does not stimulate proliferation.

Livial is a once-daily oral therapy that provides a well tolerated and comprehensive treatment option for postmenopausal women. Amongst its many unique benefits, it avoids the undesired effects on the endometrium (monthly withdrawal bleeds) and breast (breast proliferation and tenderness) associated with estrogen and progestogen therapies. Organon introduced Livial in The Netherlands in 1988 and the product is now available in over 85 countries. Livial continues to be the subject of an ambitious clinical research program to identify the full extent of its unique tissue selective benefits. This program collectively will involve more than 10,000 women.